KMT2A and acute lymphoblastic leukemia: FRYL was first identified as a novel fusion partner of the mixed lineage leukemia (MLL) gene that was reported in patients who developed treatment-related acute lymphoblastic leukemia (ALL) (Hayette et al., 2005; Sait et al., 2007).